Topper James N
Insider CIK 1341382 · FOLD Director · GKOS 10% owner · COLL 10% owner · PTLA Director · SRRA Director, 10% owner · ANAB Director, 10% owner · ALNA Director, 10% owner · ALPN Director, 10% owner · APTX Director, 10% owner · ETTX Director, 10% owner · MIRM 10% owner · MBX 10% owner · PHAT Director, 10% owner · PASG 10% owner · ARQT 10% owner · TARS 10% owner · FLAC Chief Executive Officer, Director · HLVX 10% owner · NAMS Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals, I | A Award | 2026-05-19 | 2026-05-21 | 24,122 | — | $0 | 66,718 | SEC↗ |
| MBX MBX Biosciences, Inc. | P Buy | 2025-09-26 | 2025-09-30 | 666,666 | $18.00 | $12.00M | 5,219,440 | SEC↗ |
| HLVX HilleVax, Inc. | U Tender | 2025-09-17 | 2025-09-17 | 17,199 | $1.95 | $33.5K | 0 | SEC↗ |
| HLVX HilleVax, Inc. | U Tender | 2025-09-17 | 2025-09-17 | 8,535,337 | $1.95 | $16.64M | 0 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2025-09-15 | 2025-09-17 | 660 | $23.70 | $15.6K | 3,028,524 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2025-09-08 | 2025-09-10 | 1,260 | $24.99 | $31.5K | 3,027,864 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2025-08-11 | 2025-08-13 | 471 | $23.98 | $11.3K | 3,026,604 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2025-06-25 | 2025-06-26 | 1,260 | $18.26 | $23.0K | 3,026,133 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2025-06-24 | 2025-06-26 | 2,520 | $18.43 | $46.4K | 3,024,873 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2025-06-16 | 2025-06-18 | 8,584 | $19.50 | $167.4K | 3,022,153 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | A Award deriv | 2025-06-03 | 2025-06-05 | 17,500 | — | $0 | 17,500 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | A Award | 2025-06-03 | 2025-06-05 | 10,500 | — | $0 | 42,596 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | P Buy | 2025-05-21 | 2025-05-23 | 3,780 | $3.86 | $14.6K | 59,403 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | P Buy | 2025-05-14 | 2025-05-15 | 6,300 | $3.32 | $20.9K | 55,623 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | P Buy | 2025-05-13 | 2025-05-15 | 1,120 | $3.16 | $3.5K | 49,323 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | P Buy | 2025-05-12 | 2025-05-13 | 12,601 | $3.04 | $38.3K | 48,203 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | P Buy | 2025-05-09 | 2025-05-13 | 33,376 | $3.19 | $106.5K | 33,376 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | P Buy | 2025-05-09 | 2025-05-13 | 2,226 | $3.62 | $8.1K | 35,602 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2025-03-26 | 2025-03-28 | 1,135 | $22.49 | $25.5K | 3,013,569 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2025-03-04 | 2025-03-06 | 4,005 | $21.02 | $84.2K | 3,012,434 | SEC↗ |
| MBX MBX Biosciences, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 18,922,852 | — | $0 | 0 | SEC↗ |
| MBX MBX Biosciences, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 28,297,265 | — | $0 | 0 | SEC↗ |
| MBX MBX Biosciences, Inc. | P Buy | 2024-09-16 | 2024-09-17 | 625,000 | $16.00 | $10.00M | 4,552,774 | SEC↗ |
| MBX MBX Biosciences, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 3,927,774 | — | $0 | 3,927,774 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | A Award deriv | 2024-05-23 | 2024-05-24 | 17,500 | — | $0 | 17,500 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | A Award | 2024-05-23 | 2024-05-24 | 10,500 | — | $0 | 32,096 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 7,650 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 10,000 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 10,000 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 17,500 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 7,650 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 7,650 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 7,650 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | U Tender | 2024-05-18 | 2024-05-20 | 2,829,347 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | X Exercise deriv | 2024-04-25 | 2024-04-29 | 1,200,000 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | S Sale | 2024-04-25 | 2024-04-29 | 19 | $64.57 | $1.2K | 2,829,347 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | X Exercise | 2024-04-25 | 2024-04-29 | 1,200,000 | — | $0 | 2,829,366 | SEC↗ |
| HLVX HilleVax, Inc. | P Buy | 2024-04-04 | 2024-04-08 | 8,850 | $14.50 | $128.3K | 8,544,187 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2024-03-26 | 2024-03-28 | 8,429 | $21.50 | $181.2K | 3,008,429 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2024-01-02 | 2024-01-04 | 17,500 | — | $0 | 17,500 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | X Exercise deriv | 2023-12-11 | 2023-12-13 | 145,251 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | X Exercise | 2023-12-11 | 2023-12-13 | 145,251 | $12.74 | $1.85M | 1,629,366 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | P Buy | 2023-10-24 | 2023-10-26 | 80,000 | $2.50 | $200.0K | 8,764,232 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | A Award deriv | 2023-05-25 | 2023-05-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | A Award | 2023-05-25 | 2023-05-30 | 9,000 | — | $0 | 21,596 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2023-01-06 | 2023-01-10 | 10,600 | — | $0 | 10,600 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2023-01-06 | 2023-01-10 | 3,900 | — | $0 | 3,900 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2023-01-03 | 2023-01-05 | 10,000 | — | $0 | 10,000 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | A Award deriv | 2022-09-22 | 2022-09-26 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | P Buy | 2022-08-05 | 2022-08-09 | 250,000 | $20.00 | $5.00M | 8,684,232 | SEC↗ |
| HLVX HilleVax, Inc. | C Conversion deriv | 2022-05-03 | 2022-05-03 | 37,212,796 | — | $0 | 0 | SEC↗ |
| HLVX HilleVax, Inc. | P Buy | 2022-05-03 | 2022-05-03 | 1,764,706 | $17.00 | $30.00M | 8,535,337 | SEC↗ |
| HLVX HilleVax, Inc. | C Conversion | 2022-05-03 | 2022-05-03 | 2,736,234 | $13.60 | $37.21M | 6,770,631 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | P Buy | 2022-02-11 | 2022-02-15 | 112,665 | $7.10 | $799.9K | 1,484,115 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2022-02-10 | 2022-02-14 | 9,200 | — | $0 | 9,200 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2022-01-03 | 2022-01-04 | 10,000 | — | $0 | 10,000 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2021-09-17 | 2021-09-21 | 1,200,000 | — | $0 | 1,200,000 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer | 2021-09-17 | 2021-09-21 | 1,200,000 | — | $0 | 1,371,450 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | J Other | 2021-05-10 | 2021-05-12 | 96,574 | — | $0 | 96,574 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | J Other | 2021-05-10 | 2021-05-12 | 96,574 | — | $0 | 0 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | J Other | 2021-05-10 | 2021-05-12 | 2,108,558 | — | $0 | 8,434,232 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2021-02-10 | 2021-02-12 | 11,000 | — | $0 | 11,000 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2021-01-04 | 2021-01-05 | 7,650 | — | $0 | 7,650 | SEC↗ |
| FLAC Frazier Lifesciences Acqui | A Award deriv | 2020-12-11 | 2020-12-11 | 333,333 | — | $0 | 333,333 | SEC↗ |
| FLAC Frazier Lifesciences Acqui | A Award deriv | 2020-12-11 | 2020-12-11 | 167,000 | — | $0 | 167,000 | SEC↗ |
| FLAC Frazier Lifesciences Acqui | A Award | 2020-12-11 | 2020-12-11 | 501,000 | $10.00 | $5.01M | 501,000 | SEC↗ |
| FLAC Frazier Lifesciences Acqui | P Buy | 2020-12-11 | 2020-12-11 | 1,000,000 | $10.00 | $10.00M | 1,000,000 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | A Award deriv | 2020-11-17 | 2020-11-18 | 14,000 | — | $0 | 14,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | J Other | 2020-11-16 | 2020-11-18 | 26,354 | — | $0 | 80,812 | SEC↗ |
| ANAB ANAPTYSBIO, INC | J Other | 2020-11-16 | 2020-11-18 | 22,604 | — | $0 | 54,458 | SEC↗ |
| ANAB ANAPTYSBIO, INC | J Other | 2020-11-16 | 2020-11-18 | 98,275 | — | $0 | 199,529 | SEC↗ |
| ANAB ANAPTYSBIO, INC | J Other | 2020-11-16 | 2020-11-18 | 344,860 | — | $0 | 700,171 | SEC↗ |
| ANAB ANAPTYSBIO, INC | J Other | 2020-11-16 | 2020-11-18 | 973,612 | — | $0 | 0 | SEC↗ |
| TARS Tarsus Pharmaceuticals, In | C Conversion deriv | 2020-10-20 | 2020-10-20 | 214,281 | — | $0 | 0 | SEC↗ |
| TARS Tarsus Pharmaceuticals, In | C Conversion deriv | 2020-10-20 | 2020-10-20 | 1,390,376 | — | $0 | 0 | SEC↗ |
| TARS Tarsus Pharmaceuticals, In | P Buy | 2020-10-20 | 2020-10-20 | 312,500 | $16.00 | $5.00M | 1,917,157 | SEC↗ |
| TARS Tarsus Pharmaceuticals, In | C Conversion | 2020-10-20 | 2020-10-20 | 214,281 | — | $0 | 1,604,657 | SEC↗ |
| TARS Tarsus Pharmaceuticals, In | C Conversion | 2020-10-20 | 2020-10-20 | 1,390,376 | — | $0 | 1,390,376 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | J Other | 2020-06-12 | 2020-06-16 | 1,456,854 | — | $0 | 5,827,415 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | A Award deriv | 2020-05-21 | 2020-05-22 | 10,000 | — | $0 | 10,000 | SEC↗ |
| APTX Aptinyx Inc. | A Award | 2020-03-31 | 2020-04-02 | 4,976 | $2.16 | $10.7K | 3,195,055 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 2,977,242 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 1,049,175 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 432,802 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 432,802 | — | $0 | 4,459,219 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 2,977,242 | — | $0 | 2,977,242 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 1,049,175 | — | $0 | 4,026,417 | SEC↗ |
| PASG Passage BIO, Inc. | P Buy | 2020-03-03 | 2020-03-03 | 550,000 | $18.00 | $9.90M | 5,009,219 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2020-02-12 | 2020-02-13 | 11,000 | — | $0 | 11,000 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion deriv | 2020-02-04 | 2020-02-06 | 2,099,019 | — | $0 | 0 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion deriv | 2020-02-04 | 2020-02-06 | 6,360,272 | — | $0 | 0 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion deriv | 2020-02-04 | 2020-02-06 | 1,074,467 | — | $0 | 0 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion | 2020-02-04 | 2020-02-06 | 6,360,272 | — | $0 | 6,869,304 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion | 2020-02-04 | 2020-02-06 | 2,099,019 | — | $0 | 8,968,323 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion | 2020-02-04 | 2020-02-06 | 1,074,467 | — | $0 | 10,042,790 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | P Buy | 2020-02-04 | 2020-02-06 | 500,000 | $17.00 | $8.50M | 10,542,790 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | S Sale | 2020-01-09 | 2020-01-13 | 50,000 | $5.00 | $250.0K | 1,299,953 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2020-01-02 | 2020-01-06 | 7,650 | — | $0 | 7,650 | SEC↗ |
| APTX Aptinyx Inc. | A Award deriv | 2019-12-31 | 2020-01-03 | 5,018 | $2.14 | $10.7K | 5,018 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | C Conversion deriv | 2019-10-29 | 2019-10-30 | 0 | — | $0 | 0 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | C Conversion | 2019-10-29 | 2019-10-30 | 1,353,640 | $15.20 | $20.58M | 6,231,638 | SEC↗ |
| PHAT Phathom Pharmaceuticals, I | P Buy | 2019-10-29 | 2019-10-30 | 1,052,631 | $19.00 | $20.00M | 7,284,269 | SEC↗ |
| APTX Aptinyx Inc. | A Award deriv | 2019-09-30 | 2019-10-02 | 5,162 | $2.08 | $10.7K | 5,162 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | C Conversion deriv | 2019-07-22 | 2019-07-24 | 24,935,300 | — | $0 | 0 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | P Buy | 2019-07-22 | 2019-07-24 | 450,000 | $15.00 | $6.75M | 3,566,912 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | C Conversion | 2019-07-22 | 2019-07-24 | 3,116,912 | — | $0 | 3,116,912 | SEC↗ |
| APTX Aptinyx Inc. | A Award deriv | 2019-06-28 | 2019-07-02 | 5,424 | $1.98 | $10.7K | 5,424 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | A Award deriv | 2019-06-05 | 2019-06-07 | 14,000 | — | $0 | 14,000 | SEC↗ |
| APTX Aptinyx Inc. | A Award deriv | 2019-05-15 | 2019-05-17 | 40,000 | — | $0 | 40,000 | SEC↗ |
| APTX Aptinyx Inc. | A Award deriv | 2019-03-29 | 2019-04-02 | 4,433 | $2.43 | $10.8K | 4,433 | SEC↗ |
| ANAB ANAPTYSBIO INC | A Award deriv | 2019-02-08 | 2019-02-11 | 6,000 | — | $0 | 6,000 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | A Award deriv | 2019-01-18 | 2019-01-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | P Buy deriv | 2019-01-18 | 2019-01-22 | 145,251 | — | $0 | 145,251 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | P Buy | 2019-01-18 | 2019-01-22 | 372,439 | $5.37 | $2.00M | 2,571,450 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2019-01-02 | 2019-01-04 | 7,650 | — | $0 | 7,650 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion deriv | 2018-09-28 | 2018-10-02 | 6,651,574 | — | $0 | 0 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion deriv | 2018-09-28 | 2018-10-02 | 5,212,833 | — | $0 | 0 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion deriv | 2018-09-28 | 2018-10-02 | 7,000,000 | — | $0 | 0 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion | 2018-09-28 | 2018-10-02 | 337,707 | — | $0 | 337,707 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | P Buy | 2018-09-28 | 2018-10-02 | 375,887 | $15.00 | $5.64M | 1,349,953 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion | 2018-09-28 | 2018-10-02 | 320,898 | — | $0 | 974,066 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion | 2018-09-28 | 2018-10-02 | 251,487 | — | $0 | 589,194 | SEC↗ |
| APTX Aptinyx Inc. | C Conversion deriv | 2018-06-25 | 2018-06-26 | 28,895,188 | — | $0 | 0 | SEC↗ |
| APTX Aptinyx Inc. | C Conversion deriv | 2018-06-25 | 2018-06-26 | 33,022,786 | — | $0 | 0 | SEC↗ |
| APTX Aptinyx Inc. | C Conversion deriv | 2018-06-25 | 2018-06-26 | 21,946,301 | — | $0 | 0 | SEC↗ |
| APTX Aptinyx Inc. | C Conversion | 2018-06-25 | 2018-06-26 | 1,047,450 | — | $0 | 1,047,450 | SEC↗ |
| APTX Aptinyx Inc. | C Conversion | 2018-06-25 | 2018-06-26 | 1,197,076 | — | $0 | 2,244,526 | SEC↗ |
| APTX Aptinyx Inc. | P Buy | 2018-06-25 | 2018-06-26 | 150,000 | $16.00 | $2.40M | 3,190,079 | SEC↗ |
| APTX Aptinyx Inc. | C Conversion | 2018-06-25 | 2018-06-26 | 795,553 | — | $0 | 3,040,079 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | A Award deriv | 2018-06-08 | 2018-06-12 | 10,182 | — | $0 | 10,182 | SEC↗ |
| ANAB ANAPTYSBIO INC | J Other | 2018-05-11 | 2018-05-15 | 301,024 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | J Other | 2018-05-11 | 2018-05-15 | 1,372,000 | — | $0 | 973,612 | SEC↗ |
| ANAB ANAPTYSBIO INC | J Other | 2018-05-11 | 2018-05-15 | 31,854 | — | $0 | 31,854 | SEC↗ |
| ANAB ANAPTYSBIO INC | J Other | 2018-05-11 | 2018-05-15 | 301,024 | — | $0 | 301,024 | SEC↗ |
| ANAB ANAPTYSBIO INC | A Award deriv | 2018-02-02 | 2018-02-06 | 6,000 | — | $0 | 6,000 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2018-01-02 | 2018-01-04 | 7,650 | — | $0 | 7,650 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | C Conversion deriv | 2017-11-06 | 2017-11-06 | 4,629,630 | — | $0 | 0 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | C Conversion deriv | 2017-11-06 | 2017-11-06 | 6,122,448 | — | $0 | 0 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | C Conversion deriv | 2017-11-06 | 2017-11-06 | 1,061,904 | — | $0 | 0 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | C Conversion | 2017-11-06 | 2017-11-06 | 1,466,805 | — | $0 | 1,466,805 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | C Conversion | 2017-11-06 | 2017-11-06 | 1,109,159 | — | $0 | 2,575,964 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | C Conversion | 2017-11-06 | 2017-11-06 | 254,409 | — | $0 | 2,830,373 | SEC↗ |
| ALNA Allena Pharmaceuticals, In | P Buy | 2017-11-06 | 2017-11-06 | 500,000 | $14.00 | $7.00M | 3,330,373 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award | 2017-07-24 | 2017-07-26 | 2,199,011 | — | $0 | 2,199,011 | SEC↗ |
| ANAB ANAPTYSBIO INC | A Award deriv | 2017-02-24 | 2017-02-28 | 15,000 | — | $0 | 15,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | P Buy | 2017-02-14 | 2017-02-16 | 5,925,926 | $1.35 | $8.00M | 5,925,926 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 733,740 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 604,055 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 1,428,571 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 195,751 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 209,095 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 2,228,377 | — | $0 | 2,228,377 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 733,740 | — | $0 | 733,740 | SEC↗ |
| ANAB ANAPTYSBIO INC | P Buy | 2017-01-31 | 2017-01-31 | 311,291 | $15.00 | $4.67M | 1,045,031 | SEC↗ |
| ANAB ANAPTYSBIO INC | P Buy | 2017-01-31 | 2017-01-31 | 88,709 | $15.00 | $1.33M | 297,804 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 209,095 | — | $0 | 209,095 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | A Award deriv | 2016-06-16 | 2016-06-20 | 38,835 | — | $0 | 38,835 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | C Conversion deriv | 2015-07-21 | 2015-07-21 | 1,869,606 | — | $0 | 0 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | J Other | 2015-07-21 | 2015-07-21 | 96,589 | $5.22 | $504.2K | 1,966,195 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | P Buy | 2015-07-21 | 2015-07-21 | 220,000 | $17.00 | $3.74M | 2,186,195 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | C Conversion | 2015-07-21 | 2015-07-21 | 1,869,606 | — | $0 | 1,869,606 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion deriv | 2015-06-30 | 2015-06-30 | 151,653 | — | $0 | 0 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion deriv | 2015-06-30 | 2015-06-30 | 253,390 | — | $0 | 0 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion deriv | 2015-06-30 | 2015-06-30 | 1,523,809 | — | $0 | 0 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion deriv | 2015-06-30 | 2015-06-30 | 674,510 | — | $0 | 0 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion | 2015-06-30 | 2015-06-30 | 2,603,362 | — | $0 | 2,603,362 | SEC↗ |
| GKOS GLAUKOS Corp | X Exercise deriv | 2015-06-26 | 2015-06-30 | 24,705 | $7.65 | $189.0K | 674,510 | SEC↗ |
| GKOS GLAUKOS Corp | X Exercise deriv | 2015-06-26 | 2015-06-30 | 24,705 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion deriv | 2015-05-12 | 2015-05-14 | 2,705,585 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion deriv | 2015-05-12 | 2015-05-14 | 4,019,183 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion deriv | 2015-05-12 | 2015-05-14 | 3,676,078 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion deriv | 2015-05-12 | 2015-05-14 | 1,533,399 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion | 2015-05-12 | 2015-05-14 | 582,490 | — | $0 | 582,490 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | P Buy | 2015-05-12 | 2015-05-14 | 150,000 | $12.00 | $1.80M | 1,887,332 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion | 2015-05-12 | 2015-05-14 | 540,498 | — | $0 | 1,737,332 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion | 2015-05-12 | 2015-05-14 | 392,113 | — | $0 | 1,196,834 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion | 2015-05-12 | 2015-05-14 | 222,231 | — | $0 | 804,721 | SEC↗ |
| FOLD AMICUS THERAPEUTICS INC | A Award deriv | 2014-06-12 | 2014-06-16 | 15,000 | — | $0 | 15,000 | SEC↗ |
| FOLD AMICUS THERAPEUTICS INC | A Award deriv | 2013-06-13 | 2013-06-17 | 15,000 | — | $0 | 15,000 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | A Award deriv | 2013-06-05 | 2013-06-07 | 14,101 | — | $0 | 14,101 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion deriv | 2013-05-28 | 2013-05-30 | 223,383 | — | $0 | 0 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion deriv | 2013-05-28 | 2013-05-30 | 430 | — | $0 | 0 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion deriv | 2013-05-28 | 2013-05-30 | 517,243 | — | $0 | 0 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion deriv | 2013-05-28 | 2013-05-30 | 2,625 | — | $0 | 0 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion deriv | 2013-05-28 | 2013-05-30 | 84,775 | — | $0 | 0 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion deriv | 2013-05-28 | 2013-05-30 | 1,134 | — | $0 | 0 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion deriv | 2013-05-28 | 2013-05-30 | 603,553 | — | $0 | 0 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion deriv | 2013-05-28 | 2013-05-30 | 3,063 | — | $0 | 0 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion | 2013-05-28 | 2013-05-30 | 7,252 | — | $0 | 7,252 | SEC↗ |
| PTLA PORTOLA PHARMACEUTICALS IN | C Conversion | 2013-05-28 | 2013-05-30 | 1,428,954 | — | $0 | 1,428,954 | SEC↗ |
| FOLD AMICUS THERAPEUTICS INC | A Award deriv | 2012-06-13 | 2012-06-15 | 15,000 | — | $0 | 15,000 | SEC↗ |